{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:55:00Z","timestamp":1782932100963,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.canlet.2024.216997","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T15:58:15Z","timestamp":1716652695000},"page":"216997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma"],"prefix":"10.1016","volume":"595","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0389-1585","authenticated-orcid":false,"given":"Yoshiro","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisaku","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8828-1067","authenticated-orcid":false,"given":"Shogo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8029-5686","authenticated-orcid":false,"given":"Yoshifumi","family":"Iwagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Tomimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadafumi","family":"Asaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2318-1129","authenticated-orcid":false,"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.216997_bib1","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S2468-1253(21)00171-0","article-title":"Current and emerging therapies for advanced biliary tract cancers","volume":"6","author":"Kam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.canlet.2024.216997_bib2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2024.216997_bib3","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216997_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221115317","article-title":"Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions\/rearrangements","volume":"15","author":"Walden","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.canlet.2024.216997_bib5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.canlet.2024.216997_bib6","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216997_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41698-022-00320-5","article-title":"Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies","volume":"6","author":"Lidsky","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.canlet.2024.216997_bib8","article-title":"INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2024.216997_bib9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2024.216997_bib10","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2217\/fon-2020-0429","article-title":"FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements","volume":"16","author":"Bekaii-Saab","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.canlet.2024.216997_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120427","article-title":"Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT\/mTOR and EMT signaling pathways","volume":"296","author":"Jaidee","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.canlet.2024.216997_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12605","article-title":"Deciphering role of FGFR signalling pathway in pancreatic cancer","volume":"52","author":"Kang","year":"2019","journal-title":"Cell Prolif."},{"key":"10.1016\/j.canlet.2024.216997_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-016-3003-0","article-title":"Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective","volume":"78","author":"Ciccolini","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2024.216997_bib14","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.ejca.2012.12.002","article-title":"Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer","volume":"49","author":"Yamada","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2024.216997_bib15","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.28411","article-title":"Aspartate beta-hydroxylase modulates cellular senescence through glycogen synthase kinase 3beta in hepatocellular carcinoma","volume":"63","author":"Iwagami","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2024.216997_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145985","article-title":"A histone deacetylase inhibitor suppresses epithelial-mesenchymal transition and attenuates chemoresistance in biliary tract cancer","volume":"11","author":"Sakamoto","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2024.216997_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/cas.14709","article-title":"The blockade of interleukin-33 released by hepatectomy would be a promising treatment option for cholangiocarcinoma","volume":"112","author":"Nagaoka","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2024.216997_bib18","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1007\/s10620-021-07266-x","article-title":"Clinical significance of acylphosphatase 1 expression in combined HCC-iCCA, HCC, and iCCA","volume":"67","author":"Sakano","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.canlet.2024.216997_bib19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12906-018-2372-9","article-title":"Croton gratissimus leaf extracts inhibit cancer cell growth by inducing caspase 3\/7 activation with additional anti-inflammatory and antioxidant activities","volume":"18","author":"Mfotie Njoya","year":"2018","journal-title":"BMC Compl. Alternative Med."},{"key":"10.1016\/j.canlet.2024.216997_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/srep42339","article-title":"MicroRNA-155 controls exosome synthesis and promotes gemcitabine resistance in pancreatic ductal adenocarcinoma","volume":"7","author":"Mikamori","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2024.216997_bib21","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.1038\/s41467-021-26613-0","article-title":"Apoptotic stress-induced FGF signalling promotes non-cell autonomous resistance to cell death","volume":"12","author":"Bock","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.216997_bib22","article-title":"Progression-free survival in patients with cholangiocarcinoma with or without FGF\/FGFR alterations: a FIGHT-202 post hoc analysis of prior systemic therapy response","volume":"6","author":"Bibeau","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.canlet.2024.216997_bib23","first-page":"13","article-title":"FGF\/FGFR-Dependent molecular mechanisms underlying anti-cancer drug resistance","author":"Szymczyk","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.216997_bib24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12920-020-00794-x","article-title":"Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine","volume":"13","author":"Tong","year":"2020","journal-title":"BMC Med. Genom."},{"key":"10.1016\/j.canlet.2024.216997_bib25","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/cas.13124","article-title":"ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance","volume":"108","author":"Kikuchi","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2024.216997_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108772","article-title":"Inhibition of FGF10-ERK signal activation suppresses intraductal papillary neoplasm of the bile duct and its associated carcinomas","volume":"34","author":"Tomita","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2024.216997_bib27","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1167\/iovs.08-2378","article-title":"Activation of the FGF2\/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells","volume":"50","author":"Lefevre","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.canlet.2024.216997_bib28","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1158\/1078-0432.CCR-11-0050","article-title":"Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells","volume":"17","author":"Marshall","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216997_bib29","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/1878-0261.13145","article-title":"FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas","volume":"16","author":"Milton","year":"2022","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.canlet.2024.216997_bib30","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2024.216997_bib31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/COC.0000000000000492","article-title":"A phase ib study of the FGFR\/VEGFR inhibitor dovitinib with gemcitabine and capecitabine in advanced solid tumor and pancreatic cancer patients","volume":"42","author":"Ma","year":"2019","journal-title":"Am. J. Clin. Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524003914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524003914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T01:29:57Z","timestamp":1718242197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524003914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":31,"alternative-id":["S0304383524003914"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216997","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216997","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"216997"}}